Citius Oncology (CTOR) Accumulated Expenses (2023 - 2026)

Citius Oncology (CTOR) has reported Accumulated Expenses for 4 consecutive years, with $25.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 205.44% year-over-year to $25.8 million in Q2 2026; TTM through Jun 2026 was $25.8 million, a 205.44% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, changed N/A from the prior year.
• Accumulated Expenses was $25.8 million for Q2 2026 at Citius Oncology, up from $24.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $25.8 million in Q2 2026 and troughed at $108899.0 in Q2 2023.
• A 4-year average of $7.0 million and a median of $4.3 million in 2025 frame the typical range for Accumulated Expenses.
• The widest YoY moves for Accumulated Expenses: up 1686.47% in 2025, down 27.45% in 2025.
• Over 4 years, Accumulated Expenses stood at $375886.0 in 2023, then soared by 1557.05% to $6.2 million in 2024, then slipped by 27.45% to $4.5 million in 2025, then surged by 471.73% to $25.8 million in 2026.
• The last three Accumulated Expenses figures came in at $25.8 million (Q2 2026), $24.1 million (Q1 2026), and $4.5 million (Q4 2025), per Business Quant data.